AstraZeneca has reported a strong set of results for the first nine months and third quarter of 2025, highlighting double-digit revenue growth, rising earnings, and record progress in its late-stage pipeline. The company achieved an 11% increase in total revenue at constant exchange rates, with particularly strong performances across oncology, cardiovascular, renal and metabolism, and respiratory and immunology portfolios. Growth was broad-based across all therapy areas and geographic regions, underpinned by new launches and the sustained uptake of key medicines. Core operating profit and earnings per share also showed double-digit gains, reflecting both higher sales and improved cost discipline.
The quarter was marked by exceptional progress in innovation, with AstraZeneca announcing 16 positive Phase III trial readouts and 31 major regulatory approvals during the year to date. This scientific productivity reinforces the company’s ambition to deliver a diverse pipeline capable of driving growth well into the next decade. Among the highlights were positive data for baxdrostat in hypertension and further success for Enhertu and Datroway in breast and lung cancers. These outcomes build on the company’s leadership in targeted oncology and its expanding portfolio in cardiovascular and rare diseases. The clinical trials appendix details a strong late-stage pipeline of potential new medicines and lifecycle extensions that could contribute significantly to future revenues.
Operationally, AstraZeneca continues to focus on expanding its global footprint and manufacturing capabilities, including investment in new facilities to support biologics and next-generation therapies. The company reaffirmed its full-year guidance for both total revenue and core earnings per share, signalling confidence in sustained performance despite global economic challenges. Management emphasized disciplined execution and ongoing investment in research and development as key drivers for long-term value creation.
Overall, AstraZeneca’s Q3 2025 update underscores a business in robust health commercially strong, scientifically productive, and strategically focused. With a deep and advancing pipeline, a solid balance sheet, and a track record of delivery, the company remains well positioned to achieve its growth ambitions through 2030 and beyond.
